We are live on ! Find out more

656 hedge funds and large institutions have $13B invested in Sanofi in 2022 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 246 increasing their positions, 183 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

822% more call options, than puts

Call options by funds: $90.7M | Put options by funds: $9.84M

117% more funds holding in top 10

Funds holding in top 10: 613 (+7)

91% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 45

34% more repeat investments, than reductions

Existing positions increased: 246 | Existing positions reduced: 183

5% more funds holding

Funds holding: 623656 (+33)

0.6% more ownership

Funds ownership: 19.9%20.5% (+0.6%)

0% more capital invested

Capital invested by funds: $12.9B → $13B (+$49.6M)

Holders
656
Holders Change
+33
Holders Change %
+5.3%
% of All Funds
11.01%
Holding in Top 10
13
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+116.67%
% of All Funds
0.22%
New
86
Increased
246
Reduced
183
Closed
45
Calls
$90.7M
Puts
$9.84M
Net Calls
+$80.9M
Net Calls Change
+$13.2M

SNY Hedge Fund Activity: Q2 2022 in Review

656 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2022, worth a combined $13B — up 0.38% from $12.9B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new SNY positions and 45 closed out — a net gain of 41 holders — while 246 added to existing stakes and 183 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $567M. The largest seller was Dodge & Cox, cutting an estimated $797M.

  • 656 institutional investors held Sanofi (SNY) as of Q2 2022, up from 623 in Q1 2022.
  • Funds reported $13B of Sanofi stock for Q2 2022, up 0.38% quarter-over-quarter.
  • 86 funds opened new Sanofi positions in Q2 2022 and 45 closed out, a net change of +41 holders.
  • The largest Sanofi buyer in Q2 2022 was T. Rowe Price Associates, an estimated $567M added.
  • The largest Sanofi seller in Q2 2022 was Dodge & Cox, an estimated $797M sold.

Based on aggregated 13F filings for Q2 2022.